Volume 30, Issue 1 (March 2026)                   Physiol Pharmacol 2026, 30(1): 70-80 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ahooghalandari S B, Jalali S M, Jamshidian J, Rezaie A. Comparison of the effects of platelet-rich plasma and erythropoietin on nephropathy and hepatopathy in streptozotocin-induced diabetic rats: a biochemical, oxidative stress, and histopathological study. Physiol Pharmacol 2026; 30 (1) :70-80
URL: http://ppj.phypha.ir/article-1-2484-en.html
Comparison of the effects of platelet-rich plasma and erythropoietin on nephropathy and hepatopathy in streptozotocin-induced diabetic rats: a biochemical, oxidative stress, and histopathological study
Seyedeh Bahar Ahooghalandari , Seyedeh Missagh Jalali , Javad Jamshidian , Annahita Rezaie
Abstract:   (1806 Views)

Introduction: This research evaluates the treatment benefits of platelet-rich plasma (PRP) and erythropoietin (EPO) on diabetic nephropathy and hepatopathy in rats.
Methods: Thirty male rats were separated into five groups: control, diabetic control, PRP-treated diabetic (1 mL PRP subcutaneously twice weekly), EPO-treated diabetic (300 units/kg EPO subcutaneously three times weekly), and a combination of PRP and EPO treatment (1 mL PRP twice weekly and 300 units/kg EPO three times weekly). Diabetes was induced using streptozotocin (65 mg/kg), and treatments were administered over four weeks. Serum markers for renal and hepatic function, oxidative stress indices, and histopathological changes in liver and kidney tissues were assessed.
Results: In diabetic rats, serum urea, creatinine, and liver enzymes (ALT, AST, ALP, LDH, GGT) increased significantly (p<0.05), while treatment with PRP, EPO, or both significantly reduced ALT, AST, ALP, LDH, and GGT (except in the combined group for GGT; p>0.05). Renal and hepatic SOD decreased significantly in diabetes (p<0.05) but improved with treatment, especially in the combined group (p<0.05). Renal TAC increased in diabetes and decreased significantly after treatment (p<0.05). No significant changes were observed in GPX or MDA levels (p>0.05). Damage in kidney and liver tissues were obtained in diabetic group. Histopathological improvements were evident, in hepatocyte integrity and glomerular structure, with EPO and PRP treatments.
Conclusion: The results emphasize the potential of EPO and PRP as complementary therapeutic strategies to reduce diabetes-induced oxidative damage and structural deterioration in liver and kidney tissues. However, further adjunctive approaches are required to achieve comprehensive organ protection.

Keywords: Platelet-rich plasma, Erythropoietin, Diabetes, Kidney, Liver
Full-Text [PDF 869 kb]   (143 Downloads)    
Type of Manuscript: Experimental research article | Subject: Others
References
1. Altun G, Cakiroglu Y, Pulathan Z, Yulug E, Mentese A. Renoprotective potential of exogen erythropoietin on experimental ruptured abdominal aortic aneurysm model: An animal study. Iranian Journal of Basic Medical Sciences 2020; 23: 271.
2. Alves R, Grimalt R. A review of platelet-rich plasma: history, biology, mechanism of action, and classification. Skin Appendage Disorders 2018; 4(1): 18-24. [DOI:10.1159/000477353]
3. Arif A, Farooq A, Abbasi M H, Khawar M B, Akhtar T, Ali H A, et al. Effect of heterologous platelet-rich plasma on liver and modulation of glucose metabolism and Wnt signalling pathways in diabetic mice. Molecular Biology Reports 2023; 50: 7145-7154. [DOI:10.1007/s11033-023-08600-4]
4. Arik E, Heinisch O, Bienert M, Hoffmann A, Zschätzsch M, Michel U, et al. Erythropoietin enhances post-ischemic migration and phagocytosis and alleviates the activation of inflammasomes in human microglial cells. Frontiers in Cellular Neuroscience 2022; 16: 915348. [DOI:10.3389/fncel.2022.915348]
5. Barnett R. Type 1 diabetes. Lancet 2018; 391(10117): 195. [DOI:10.1016/S0140-6736(18)30024-2]
6. Basile D, Bonventre J, Mehta R, Nangaku M, Unwin R, Rosner M, et al. ADQI XIII Work Group. Progression after AKI: understanding maladaptive repair processes to predict and identify therapeutic treatments. Journal of the American Society of Nephrology 2016; 27(3): 687-697. [DOI:10.1681/ASN.2015030309]
7. Bin S, Cantarelli C, Horwitz J K, Li Y, Pezzolesi M G, Zhou Y, et al. Endogenous erythropoietin has immunoregulatory functions that limit the expression of autoimmune kidney disease in mice. Frontiers in Immunology 2023; 14: 1195662. [DOI:10.3389/fimmu.2023.1195662]
8. Bhatti J S, Sehrawat A, Mishra J, Sidhu I S, Navik U, Khullar N, Reddy P H. Oxidative stress in the pathophysiology of type 2 diabetes and related complications: Current therapeutics strategies and future perspectives. Free Radical Biology and Medicine 2022; 184: 114-134. [DOI:10.1016/j.freeradbiomed.2022.03.019]
9. Bancroft J D, Gamble M. theory and practice of histological techniques. 9th ed. London: Elsevier; 2023.
10. Cole J B, Florez J C. Genetics of diabetes mellitus and diabetes complications. Nature Reviews Nephrology 2020; 16: 377-390. [DOI:10.1038/s41581-020-0278-5]
11. Collister D, Komenda P, Hiebert B, Gunasekara R, Xu Y, Eng F, Lerner B, et al. The effect of erythropoietin-stimulating agents on health-related quality of life in anemia of chronic kidney disease. Annals of Internal Medicine 2016; 164(7): 472. [DOI:10.7326/M15-1839]
12. Darenskaya M, Kolesnikov S, Semenova N, Kolesnikova L. Diabetic nephropathy: significance of determining oxidative stress and opportunities for antioxidant therapies. International Journal of Molecular 2023; 24: 12378. [DOI:10.3390/ijms241512378]
13. Dey A, Lakshmanan J. The role of antioxidants and other agents in alleviating hyperglycemia mediated oxidative stress and injury in liver. Food & Function 2013; 4: 1148-1184. [DOI:10.1039/c3fo30317a]
14. Ehrenfest D M, Andia I, Zumstein M A, Zhang C Q, Pinto N R, Bielecki T. Classification of platelet concentrates (platelet-rich plasma-PRP, platelet-rich fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: Current consensus, clinical implications and perspectives. Muscles, Ligaments and Tendons Journal 2014; 4(1): 3-9. [DOI:10.32098/mltj.01.2014.02]
15. Elbaset M A, Mohamed B M, Moustafa P E, Mansour D F, Afifi S M, Esatbeyoglu T, et al. Erythropoietin suppresses the hepatic fibrosis caused by thioacetamide: role of the PI3K/Akt and TLR4 signaling pathways. Oxidative Medicine and Cellular Longevity 2023; 2023: 5514248. [DOI:10.1155/2023/5514248]
16. Etulain J, Mena H A, Meiss R P, Frechtel G, Gutt S, Negrotto S, et al. An optimised protocol for platelet-rich plasma preparation to improve its angiogenic and regenerative properties. Scientific Reports 2018; 8(1): 1513. [DOI:10.1038/s41598-018-19419-6]
17. Ghasemi-Dehnoo M, Amini-Khoei H, Lorigooini Z, Rafieian-Kopaei M. Oxidative stress and antioxidants in diabetes mellitus. Asian Pacific Journal of Tropical Medicine 2020; 13(10): 431-438. [DOI:10.4103/1995-7645.291036]
18. Kottaisamy C P D, Raj D S, Prasanth Kumar V, Sankaran U. Experimental animal models for diabetes and its related complications a review. Laboratory Animal Research 2021; 37(1): 21. [DOI:10.1186/s42826-021-00101-4]
19. Liu Q S, Cheng Z W, Xiong J G, Cheng S, He X F, Li X C. Erythropoietin pretreatment exerts anti-inflammatory effects in hepatic ischemia/reperfusion-injured rats via suppression of the TLR2/NF-κB pathway. Transplantation Proceedings 2015; 47: 283-289. [DOI:10.1016/j.transproceed.2014.10.045]
20. Mallik S, Paria B, Firdous S M, Ghazzawy H S, Alqahtani N K, He Y, Gouda M M. The positive implication of natural antioxidants on oxidative stress-mediated diabetes mellitus complications. Journal of Genetic Engineering and Biotechnology 2024; 22: 100424. [DOI:10.1016/j.jgeb.2024.100424]
21. Mateus M, Silva A M, Ribeiro C A, Sousa N, Carvalho F, Pinto L, et al. Erythropoietin prevents neuroinflammation and relieves depression via JAK/STAT signaling. Brain, Behavior, and Immunity 2023; 110: 123-135.
22. Młynarska E, Buławska D, Czarnik W, Hajdys J, Majchrowicz G, Prusinowski F, et al. Novel insights into diabetic kidney disease. International Journal of Molecular Sciences 2024; 25: 10222. [DOI:10.3390/ijms251810222]
23. Mobasheri L, Ahadi M, Namdar A B, Alavi M S, Bemidinezhad A, Farahi S M M, et al. Pathophysiology of diabetic hepatopathy and molecular mechanisms underlying the hepatoprotective effects of phytochemicals. Biomedicine & Pharmacotherapy 2023; 167: 115502. [DOI:10.1016/j.biopha.2023.115502]
24. Ndisang J F, Vannacci A, Rastogi S. Insulin resistance, type 1 and type 2 diabetes, and related complications 2017. Journal of Diabetes Research 2017; 2017: 1-3. [DOI:10.1155/2017/1478294]
25. Nekoui A, Blaise G. Erythropoietin and nonhematopoietic effects. American Journal of the Medical Sciences 2017; 353(1): 29-34. [DOI:10.1016/j.amjms.2016.10.009]
26. Palma R, Pronio A, Romeo M, Scognamiglio F, Ventriglia L, Ormando VM, et al. The role of insulin resistance in fueling NAFLD pathogenesis: from molecular mechanisms to clinical implications. Journal of Clinical Medicine 2022; 11: 3649. [DOI:10.3390/jcm11133649]
27. Peng B, Kong G, Yang C, Ming Y. Erythropoietin and its derivatives: from tissue protection to immune regulation. Cell Death & Disease 2020; 11: 79. [DOI:10.1038/s41419-020-2276-8]
28. Pineda-Cortel M R, Suarez C, Cabrera J-T, Angeles A G, Reyes R M, Paglinawan R Q. Complexity of platelet-rich plasma: Mechanism of action, growth factor utilization and variation in preparation. ournal of Clinical and Aesthetic Dermatology 2024; 17(2): 123-135. [DOI:10.1177/26348535241277625]
29. Sakashita M, Tanaka T, Inagi R. Metabolic changes and oxidative stress in diabetic kidney disease. Antioxidants 2021; 10: 1143. [DOI:10.3390/antiox10071143]
30. Samy A, El-Adl M, Rezk S, Marghani B, Eldomany W, Eldesoky A, et al. The potential protective and therapeutic effects of platelet-rich plasma on ischemia/reperfusion injury following experimental torsion/detorsion of testis in the Albino rat model. Life Sciences 2020; 256: 117982. [DOI:10.1016/j.lfs.2020.117982]
31. Saran R, Robinson B, Abbott K C. Epidemiology of kidney disease in the United States. American Journal of Kidney Diseases 2017; 69(3S1): 7-8.
32. Shivaramu S, Maiti S K, Banu S A, Kalaiselvan E, Sharun K, Mishra M, et al. Synergistic hepatoprotective effects of mesenchymal stem cells and platelet-rich plasma in a rat model of bile duct ligation-induced liver cirrhosis. Cells 2024; 13: 404. [DOI:10.3390/cells13050404]
33. Singh H, Singh R, Singh A, Singh H, Singh G, Kaur S, et al. Role of oxidative stress in diabetes-induced complications and their management with antioxidants. Archives of Physiology and Biochemistry 2024; 130: 616-641. [DOI:10.1080/13813455.2023.2243651]
34. Targher G, Lonardo A, Byrne C D. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nature Reviews Endocrinology 2018; 14(2): 99-114. [DOI:10.1038/nrendo.2017.173]
35. Unnikrishnan R, Anjana R M, Mohan V. Diabetes mellitus and its complications in India. Nature Reviews Endocrinology 2016; 12(6): 357-370. [DOI:10.1038/nrendo.2016.53]
36. Vodošek Hojs N, Bevc S, Ekart R, Hojs R. Oxidative stress markers in chronic kidney disease with emphasis on diabetic nephropathy. Antioxidants 2020; 9: 925. [DOI:10.3390/antiox9100925]
37. Wang J, Matsushita K, Zhong J, Ma L J, Yang H C, Fogo A B. Low-Dose Erythropoietin Amplifies Beneficial Effects of Angiotensin II Blockade on Glomerulosclerosis. Laboratory Investigation 2023; 103: 100015. [DOI:10.1016/j.labinv.2022.100015]
38. Wang N, Zhang C. Oxidative stress: A culprit in the progression of diabetic kidney disease. Antioxidants 2024; 13: 455. [DOI:10.3390/antiox13040455]
39. Wu Y, Yang B. Erythropoietin Receptor/β common receptor: a shining light on acute kidney injury induced by ischemia-reperfusion. Frontiers in Immunology 2021; 12: 697796. [DOI:10.3389/fimmu.2021.697796]
40. Yazihan N, Kavas G. Protective effect of erythropoietin in renal ischemia-reperfusion injury. Open Drug Discovery Journal 2010; 3: 1-6. [DOI:10.2174/1877381801002020003]
41. Yu S M W, Bonventre J V. Acute kidney injury and progression of diabetic kidney disease. Advances in Chronic Kidney Disease 2018; 25(2): 166-180. [DOI:10.1053/j.ackd.2017.12.005]
42. Zarin M, Karbalaei N, Keshtgar S, Nemati M. Platelet-rich plasma improves impaired glucose hemostasis, disrupted insulin secretion, and pancreatic oxidative stress in streptozotocin-induced diabetic rat. Growth Factors 2019; 37(5-6): 226-237. [DOI:10.1080/08977194.2020.1735382]
43. Zeng L, Ng J K C, Fung W W S, Chan G C K, Chow K M, Szeto C C. Recombinant erythropoietin treatment improves serum podocyte marker levels in diabetic kidney disease. Advances in Biomarker Sciences and Technology 2023; 5: 50-56. [DOI:10.1016/j.abst.2023.06.001]
44. Zhu L, Li P, Qin Y, Wang D, Yang L, Chen Y. Platelet-rich plasma in orthopedics: Bridging innovation and clinical applications for bone repair. Journal of Orthopaedic Surgery and Research 2024; 19(1): 45. [DOI:10.1177/10225536231224952]
45. Zoja C, Xinaris C, Macconi D. Diabetic nephropathy: novel molecular mechanisms and therapeutic targets. Frontiers in Pharmacology 2020; 11: 586892. [DOI:10.3389/fphar.2020.586892]
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.